Walleye Capital
TARA icon

Walleye Capital’s Protara Therapeutics TARA Stock Holding History

Walleye Capital’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.93M Buy
505,432
+62,031
+14% +$295K 0.01% 1552
2026
Q1 		$2.31M Buy
443,401
+297,525
+204% +$1.76M 0.01% 1357
2025
Q4 		$778K Buy
+145,876
New +$811K ﹤0.01% 2635
2025
Q3 		– Sell
-161,091
Closed -$488K – 5112
2025
Q2 		$488K Sell
161,091
-68,363
-30% -$236K ﹤0.01% 2652
2025
Q1 		$977K Buy
229,454
+8,640
+4% +$38.6K ﹤0.01% 1983
2024
Q4 		$1.17M Buy
+220,814
New +$713K ﹤0.01% 2252

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Walleye Capital's TARA Position: Q2 2026 in Review

Walleye Capital increased its Protara Therapeutics (TARA) stake by 14% in Q2 2026, buying an estimated $295K and bringing the position to 505,432 shares worth $1.93M. The position accounts for 0.01% of the portfolio, ranked #1552.

Walleye Capital first reported a position in TARA in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.31M in Q1 2026. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Walleye Capital held 505,432 shares of Protara Therapeutics worth $1.93M as of Q2 2026.
  • Walleye Capital bought 62,031 Protara Therapeutics shares in Q2 2026, an estimated $295K.
  • Protara Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1552 holding.
  • Walleye Capital first reported a position in Protara Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Walleye Capital's Protara Therapeutics position peaked at $2.31M in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.